Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Shares Issued (2016 - 2025)

Immucell (ICCC) has disclosed Shares Issued for 16 consecutive years, with -$19431.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Shares Issued changed N/A year-over-year to -$19431.0, compared with a TTM value of $4.4 million through Sep 2025, up 647.91%, and an annual FY2024 reading of $4.4 million, up 23120.62% over the prior year.
  • Shares Issued was -$19431.0 for Q2 2025 at Immucell, down from $19434.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $4.4 million in Q4 2024 and bottomed at -$26.7 million in Q2 2021.
  • Average Shares Issued over 5 years is -$2.0 million, with a median of $11680.0 recorded in 2021.
  • The sharpest move saw Shares Issued tumbled 50.0% in 2022, then soared 17023.29% in 2023.
  • Year by year, Shares Issued stood at $153644.0 in 2021, then tumbled by 100.0% to -$2.0 in 2022, then skyrocketed by 50000100.0% to $1.0 million in 2023, then skyrocketed by 335.62% to $4.4 million in 2024, then crashed by 100.45% to -$19431.0 in 2025.
  • Business Quant data shows Shares Issued for ICCC at -$19431.0 in Q2 2025, $19434.0 in Q1 2025, and $4.4 million in Q4 2024.